Author(s): Boyles JR, Bair MC, Campling BG, Jain N
Abstract Share this page
Abstract The compounds (eta5-C5H5)2TiCl2 (I), currently undergoing phase II trials, (eta5-C5H5)(eta5-C5H4CO2Me)TiCl2 (II) and C5H4CO2Me)2TiCl2 (III) are assessed for their efficacies against a small lung cancer cell line. It is found that the introduction of the electron withdrawing carbomethoxy group into the cyclopentadienyl rings increases the effectiveness of this class of drugs, such that III compares favorably with the well known cisplatin.
This article was published in J Inorg Biochem
and referenced in Biochemistry & Pharmacology: Open Access